Hanall Biopharma Co.,Ltd (009420.KS)

Growth (Per Share)

Revenue 5Y—
Revenue 3Y—
Earnings 5Y—
Earnings 3Y—
Dividend 5Y—
Dividend 3Y—

Capital Efficiency

ROIC—
ROE—
ROA—
ROTA—

Capital Structure

Market Cap1.20T
EV1.20T
Cash—
Current Ratio—
Debt/Equity—
Net Debt/EBITDA—
Show More

Select a metric from the list below to chart it

Income Statement
Dec '14
Dec '15
Dec '16
Dec '17
Dec '18
Dec '19
Dec '20
Dec '21
Dec '22
TTM
Revenue
62.4
61.8
64.0
65.0
70.9
83.7
68.4
78.4
84.9
88.6
Revenue % Chg.
9.0%
-1.1%
3.6%
1.6%
9.0%
18.1%
-18.3%
14.7%
8.3%
17.4%
Cost of Revenue
31.5
33.3
34.2
32.1
33.0
35.2
29.3
31.8
37.1
38.5
Gross Profit
30.9
28.5
29.7
32.9
37.8
48.4
39.1
46.6
47.8
50.1
Gross Profit Margin
49.5%
46.1%
46.5%
50.7%
53.4%
57.9%
57.2%
59.4%
56.3%
56.5%
R&D Expenses
6.0
4.7
6.9
7.6
8.1
7.8
7.2
8.1
12.7
14.9
Selling, General, & Admin Expenses
8.9
10.1
7.8
8.2
10.7
13.0
13.4
15.8
17.9
18.2
Other Expenses
15.4
17.0
14.8
14.4
14.8
14.5
13.9
14.9
16.0
16.8
Operating Income
0.6
-3.3
0.2
2.7
4.2
13.2
6.5
7.8
1.8
0.7
Operating Income Margin
1.0%
-5.3%
0.3%
4.2%
6.0%
15.8%
9.6%
9.9%
2.1%
0.7%
Total Other Income/Expenses Net
-10.5
-0.4
1.1
-0.7
-1.1
0.3
8.3
-1.1
-0.3
0.1
Income Before Tax
-9.8
-3.7
1.3
2.0
3.1
13.5
14.8
6.7
1.5
0.7
Income Before Tax Margin
-15.8%
-6.0%
2.0%
3.1%
4.4%
16.1%
21.7%
8.6%
1.8%
0.8%
Income Tax Expense
-0.1
1.7
-0.3
-2.5
0.5
-1.3
-0.4
-0.1
1.3
0.9
Net Income
-9.8
-5.5
1.6
4.5
2.5
14.8
15.3
6.9
0.2
-0.1
Net Income Margin
-15.7%
-8.8%
2.4%
6.9%
3.6%
17.7%
22.3%
8.8%
0.2%
-0.1%
Weighted Avg. Shares Out
40.3
44.4
50.7
51.1
51.2
51.1
51.2
51.1
51.2
47.5
EPS
-0.2
-0.1
0.0
0.1
0.0
0.3
0.3
0.1
0.0
-0.0
EPS % Chg.
40.6%
49.4%
—
185.0%
-43.9%
485.9%
2.9%
-54.9%
-97.2%
—
Weighted Avg. Shares Out Dil
40.3
44.4
50.7
51.1
51.2
51.1
51.2
51.1
51.2
47.5
EPS Diluted
-0.2
-0.1
0.0
0.1
0.0
0.3
0.3
0.1
0.0
-0.0
Interest Income
0.3
0.4
0.8
0.7
1.5
1.7
1.7
0.6
1.1
1.1
Interest Expense
0.8
0.5
—
—
—
0.0
0.0
0.0
0.0
0.0
EBIT
-10.4
-3.8
2.1
2.7
4.6
15.1
16.5
7.3
2.6
1.8
EBIT Margin
-16.6%
-6.2%
3.3%
4.2%
6.4%
18.1%
24.1%
9.2%
3.0%
2.0%
Depreciation & Amortization
1.7
1.8
1.7
1.7
1.5
4.2
2.2
2.2
2.4
2.8
EBITDA
-8.6
-2.1
3.8
4.4
6.1
19.3
18.7
9.5
4.9
4.5
EBITDA Margin
-13.8%
-3.3%
6.0%
6.8%
8.6%
23.1%
27.4%
12.1%
5.8%
5.1%